Tenecteplase
Neuroprotection
Capital Medical Universityprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Neuroprotection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human Plasminogen Activator Capital Medical University | Phase 2 | B |
Darbepoetin Alfa University of Pennsylvania | Phase 2 | B |
Oxygen Capital Medical University | Phase 2 | B |
Tirofiban Capital Medical University | Phase 2 | B |
3-N-BUTYLPHTHALIDE Hui-Sheng Chen | N/A | D |
Same molecule, other indications
Tenecteplase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →